TY - JOUR
T1 - Immunohistochemical Analysis Using Antipodocalyxin Monoclonal Antibody PcMab-47 Demonstrates Podocalyxin Expression in Oral Squamous Cell Carcinomas
AU - Itai, Shunsuke
AU - Yamada, Shinji
AU - Kaneko, Mika K.
AU - Harada, Hiroyuki
AU - Kato, Yukinari
N1 - Funding Information:
We thank Takuro Nakamura, Miyuki Yanaka, Noriko Saidoh, Saori Handa, and Yoshimi Nakamura for excellent technical assistance. This work was supported, in part, by the Basic Science and Platform Technology Program for Innovative Biological Medicine from Japan Agency for Medical Research and development, AMED (Y.K.). This work was also supported, in part, by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) from AMED (Y.K.), by project for utilizing glycans in the development of innovative drug discovery technologies from AMED (Y.K.), by the Platform for Drug Discovery, Informatics, and Structural Life Science (PDIS) from AMED (Y.K.), and by JSPS KAKENHI Grant Number 17K07299 (M.K.K.) and 16K10748 (Y.K.).
Funding Information:
Y.K. received research funding from Ono Pharmaceutical Co., Ltd.
PY - 2017/10
Y1 - 2017/10
N2 - Podocalyxin is a CD34-related type I transmembrane protein that is highly glycosylated with N-glycan, O-glycan, and keratan sulfate. Podocalyxin was originally found in the podocytes of rat kidney and is reportedly expressed in many types of tumors, including brain tumors, colorectal cancers, and breast cancers. Overexpression of podocalyxin is an independent predictor of progression, metastasis, and poor outcome. We recently immunized mice with recombinant human podocalyxin, which was produced using LN229 glioblastoma cells, and produced a novel antipodocalyxin monoclonal antibody (mAb), PcMab-47, which reacts with endogenous podocalyxin-expressing cancer cell lines and normal cell lines independent of glycosylation in Western blot, flow cytometry, and immunohistochemical analyses. In this study, we performed immunohistochemical analysis against oral cancers using PcMab-47. PcMab-47-stained oral squamous cell carcinoma cells in a cytoplasmic pattern and detected 26/38 (68.4%) of oral squamous cell carcinoma cells on tissue microarrays. These results indicate that PcMab-47 is useful in detecting podocalyxin of oral cancers for immunohistochemical analysis.
AB - Podocalyxin is a CD34-related type I transmembrane protein that is highly glycosylated with N-glycan, O-glycan, and keratan sulfate. Podocalyxin was originally found in the podocytes of rat kidney and is reportedly expressed in many types of tumors, including brain tumors, colorectal cancers, and breast cancers. Overexpression of podocalyxin is an independent predictor of progression, metastasis, and poor outcome. We recently immunized mice with recombinant human podocalyxin, which was produced using LN229 glioblastoma cells, and produced a novel antipodocalyxin monoclonal antibody (mAb), PcMab-47, which reacts with endogenous podocalyxin-expressing cancer cell lines and normal cell lines independent of glycosylation in Western blot, flow cytometry, and immunohistochemical analyses. In this study, we performed immunohistochemical analysis against oral cancers using PcMab-47. PcMab-47-stained oral squamous cell carcinoma cells in a cytoplasmic pattern and detected 26/38 (68.4%) of oral squamous cell carcinoma cells on tissue microarrays. These results indicate that PcMab-47 is useful in detecting podocalyxin of oral cancers for immunohistochemical analysis.
KW - Podocalyxin
KW - immunohistochemistry
KW - monoclonal antibody
KW - oral cancer
UR - http://www.scopus.com/inward/record.url?scp=85032017965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032017965&partnerID=8YFLogxK
U2 - 10.1089/mab.2017.0030
DO - 10.1089/mab.2017.0030
M3 - Article
C2 - 28873000
AN - SCOPUS:85032017965
VL - 36
SP - 220
EP - 223
JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
SN - 2167-9436
IS - 5
ER -